• Consensus Rating: Moderate Buy
  • Consensus Price Target: $143.57
  • Forecasted Upside: 30.92%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$109.66
▲ +2.21 (2.06%)

This chart shows the closing price for MASI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Masimo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MASI

Analyst Price Target is $143.57
▲ +30.92% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Masimo in the last 3 months. The average price target is $143.57, with a high forecast of $170.00 and a low forecast of $86.00. The average price target represents a 30.92% upside from the last price of $109.66.

This chart shows the closing price for MASI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Masimo. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/9/2024Needham & Company LLCReiterated RatingHoldLow
6/3/2024Piper SandlerUpgradeNeutral ➝ Overweight$126.00 ➝ $160.00Low
5/8/2024Piper SandlerBoost TargetNeutral ➝ Neutral$117.00 ➝ $126.00Low
5/8/2024Needham & Company LLCReiterated RatingHoldLow
4/15/2024Stifel NicolausUpgradeHold ➝ Buy$148.00 ➝ $170.00Low
3/25/2024Stifel NicolausBoost TargetHold ➝ Hold$125.00 ➝ $148.00Low
3/25/2024BTIG ResearchBoost TargetBuy ➝ Buy$145.00 ➝ $166.00Low
3/25/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$117.00 ➝ $160.00Low
2/26/2024Piper SandlerBoost TargetNeutral ➝ Neutral$70.00 ➝ $117.00Low
1/30/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$107.00 ➝ $121.00Low
1/3/2024Needham & Company LLCDowngradeBuy ➝ HoldLow
11/8/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$110.00 ➝ $81.00Low
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$136.00 ➝ $86.00Low
11/8/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
8/10/2023Raymond JamesLower TargetOutperform ➝ Outperform$198.00 ➝ $142.00N/A
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$136.00Low
8/9/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$126.00 ➝ $110.00Low
7/18/2023BTIG ResearchLower Target$200.00 ➝ $153.00Low
7/18/2023Needham & Company LLCLower TargetBuy$207.00 ➝ $136.00Low
7/18/2023Wells Fargo & CompanyLower TargetEqual Weight$173.00 ➝ $126.00Low
7/18/2023Stifel NicolausDowngradeBuy ➝ Hold$205.00 ➝ $120.00Low
7/10/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$173.00Low
5/10/2023Stifel NicolausBoost Target$200.00 ➝ $205.00Low
5/10/2023Needham & Company LLCBoost Target$192.00 ➝ $207.00Low
4/17/2023BTIG ResearchBoost TargetBuy$195.00 ➝ $200.00Low
3/1/2023Raymond JamesBoost TargetOutperform$187.00 ➝ $198.00Low
3/1/2023Needham & Company LLCBoost TargetBuy$173.00 ➝ $192.00Low
3/1/2023Piper SandlerBoost TargetNeutral$135.00 ➝ $150.00Low
3/1/2023BTIG ResearchBoost Target$180.00 ➝ $195.00Low
2/22/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$187.00Low
1/11/2023Needham & Company LLCReiterated RatingBuy$173.00Low
1/11/2023Stifel NicolausBoost TargetBuy$164.00 ➝ $170.00Low
12/15/2022BTIG ResearchUpgradeNeutral ➝ Buy$180.00Low
12/5/2022Needham & Company LLCBoost TargetBuy$149.00 ➝ $173.00Low
11/9/2022Piper SandlerLower TargetNeutral$150.00 ➝ $135.00N/A
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$180.00Low
9/23/2022Piper SandlerBoost TargetNeutral$135.00 ➝ $150.00Low
9/15/2022Wolfe ResearchUpgradePeer Perform ➝ Outperform$165.00Low
9/13/2022Loop CapitalInitiated CoverageBuy$206.00Low
9/12/2022Stifel NicolausBoost TargetBuy$162.00 ➝ $172.00Low
8/10/2022Needham & Company LLCBoost TargetBuy$163.00 ➝ $179.00Low
8/10/2022Piper SandlerBoost TargetNeutral$130.00 ➝ $135.00Low
5/4/2022Stifel NicolausLower Target$175.00 ➝ $150.00Medium
5/4/2022Needham & Company LLCLower Target$205.00 ➝ $163.00High
5/4/2022Piper SandlerLower Target$160.00 ➝ $130.00High
4/5/2022Wolfe ResearchInitiated CoverageMarket Perform$160.00Low
3/31/2022Stifel NicolausLower TargetBuy$250.00 ➝ $175.00High
3/17/2022Piper SandlerLower TargetNeutral$200.00 ➝ $160.00High
2/18/2022Needham & Company LLCUpgradeHold ➝ Buy$205.00High
2/16/2022UBS GroupLower TargetBuy$325.00 ➝ $295.00High
2/16/2022Piper SandlerDowngradeOverweight ➝ Neutral$330.00 ➝ $200.00High
11/15/2021Piper SandlerBoost TargetOverweight$320.00 ➝ $330.00Low
10/27/2021Piper SandlerBoost TargetPositive ➝ Overweight$300.00 ➝ $320.00Low
10/12/2021Raymond JamesInitiated CoverageMarket PerformHigh
7/28/2021Piper SandlerBoost TargetOverweight$295.00 ➝ $300.00Low
4/29/2021Robert W. BairdReiterated RatingBuy$310.00Low
3/24/2021Piper SandlerLower TargetOverweight$310.00 ➝ $295.00Low
1/29/2021Raymond JamesBoost TargetOutperform$275.00 ➝ $285.00Low
1/14/2021Piper SandlerBoost TargetOverweight$280.00 ➝ $310.00High
10/28/2020Stifel NicolausBoost TargetBuy$255.00 ➝ $276.00High
10/28/2020Raymond JamesBoost TargetOutperform$250.00 ➝ $275.00High
10/28/2020Piper SandlerBoost TargetOverweight$250.00 ➝ $280.00High
10/6/2020Needham & Company LLCReiterated RatingHoldHigh
9/16/2020Raymond JamesReiterated RatingBuyLow
9/1/2020Robert W. BairdInitiated CoverageOutperform$260.00High
7/29/2020Stifel NicolausBoost TargetBuy$245.00 ➝ $255.00High
7/29/2020Raymond JamesBoost TargetOutperform$235.00 ➝ $250.00High
7/9/2020BTIG ResearchReiterated RatingHoldLow
6/26/2020Raymond JamesReiterated RatingBuyMedium
4/30/2020UBS GroupBoost TargetBuy$207.00 ➝ $245.00Medium
4/29/2020Stifel NicolausBoost TargetBuy$200.00 ➝ $245.00High
4/20/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
4/1/2020Needham & Company LLCReiterated RatingBuy$201.00Low
3/24/2020Needham & Company LLCReiterated RatingBuy$201.00Low
3/2/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$183.00High
2/20/2020Piper SandlerBoost Target$175.00 ➝ $201.00Low
2/20/2020Needham & Company LLCBoost TargetBuy$182.00 ➝ $201.00Medium
2/20/2020UBS GroupBoost TargetBuy$190.00 ➝ $207.00Medium
1/15/2020Piper SandlerReiterated RatingBuy$175.00Low
1/15/2020UBS GroupBoost TargetBuy$180.00 ➝ $190.00High
12/17/2019Piper Sandler CompaniesReiterated RatingOverweight$161.00 ➝ $175.00Low
8/1/2019Stifel NicolausBoost TargetBuy$165.00 ➝ $170.00Medium
8/1/2019UBS GroupBoost TargetBuy$172.00 ➝ $180.00Medium
8/1/2019BTIG ResearchReiterated RatingHoldHigh
(Data available from 7/23/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 17 positive mentions
  • 8 negative mentions
  • 9 very negative mentions
12/26/2023
  • 12 very positive mentions
  • 35 positive mentions
  • 12 negative mentions
  • 27 very negative mentions
1/25/2024
  • 24 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
2/24/2024
  • 19 very positive mentions
  • 25 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
3/25/2024
  • 15 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
4/24/2024
  • 19 very positive mentions
  • 42 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
5/24/2024
  • 13 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024
  • 12 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
7/23/2024

Current Sentiment

  • 12 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Masimo logo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $109.66
Low: $107.31
High: $109.96

50 Day Range

MA: $122.30
Low: $106.76
High: $135.80

52 Week Range

Now: $109.66
Low: $75.22
High: $153.93

Volume

456,082 shs

Average Volume

639,808 shs

Market Capitalization

$5.83 billion

P/E Ratio

74.60

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Masimo?

The following sell-side analysts have issued reports on Masimo in the last twelve months: BTIG Research, Jefferies Financial Group Inc., Needham & Company LLC, Piper Sandler, Raymond James, Stifel Nicolaus, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for MASI.

What is the current price target for Masimo?

7 Wall Street analysts have set twelve-month price targets for Masimo in the last year. Their average twelve-month price target is $143.57, suggesting a possible upside of 30.9%. Stifel Nicolaus has the highest price target set, predicting MASI will reach $170.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $86.00 for Masimo in the next year.
View the latest price targets for MASI.

What is the current consensus analyst rating for Masimo?

Masimo currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MASI.

What other companies compete with Masimo?

How do I contact Masimo's investor relations team?

Masimo's physical mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider's listed phone number is (949) 297-7000 and its investor relations email address is [email protected]. The official website for Masimo is www.masimo.com. Learn More about contacing Masimo investor relations.